NCTD promotes Birinapant-mediated anticancer activity in breast cancer cells by downregulation of c-FLIP


Second mitochondria-derived activator of caspases (SMAC) mimetics is a class of new anticancer agents. However, most cancers exhibit de novo or acquired resistance to SMAC mimetics, posting a problem for broad applications in clinic, and highlighting the necessity of exploring combinational strategies to circumvent SMAC mimetic-resistance. We here showed… (More)
DOI: 10.18632/oncotarget.15848